Dental Care Clinics in Westbrook, ME Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 John Skvorak Jr., D.m.d. Dentist Medicare: Not Enrolled in Medicare Practice Location: 390 Bridgton Rd, Westbrook, ME 04092 Phone: 207-797-7400 Fax: 207-878-9673 |
Nano Dentistry, P.a. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 13 Pleasant St, Westbrook, ME 04092 Phone: 207-856-6724 Fax: 207-856-2277 |
Main Street Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 808 Main St, Westbrook, ME 04092 Phone: 207-856-6121 |
Ducor Dent Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 395a Bridgton Rd, Westbrook, ME 04092 Phone: 207-878-8181 |
Westbrook Family Dentistry Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 100 Larrabee Rd Ste 160, Westbrook, ME 04092 Phone: 207-591-0882 |
News Archive
Discovery of novel mechanism controlling tumor growth in the brain
As survival rates among some patients with cancer continue to rise, so does the spread of these cancers to the brain - as much as 40 percent of all diagnosed brain cancers are considered metastatic, having spread from a primary cancer elsewhere in the body.
Newly developed spheroidal structure reproduces the microenvironment of tumors
Every tumor is different, every patient is different. So how do we know which treatment will work best for the patient and eradicate the cancer? In order to offer a personalised treatment that best suits the case being treated, a team of scientists led by the University of Geneva (UNIGE), Switzerland, had already developed a spheroidal reproduction of tumors that integrates the tumor cells, but also their microenvironment.
Bipolar disorder a growing health issue
The estimated number of youth with office visits with a diagnosis of bipolar disorder substantially increased between 1994 and 2003, while adult visits with a bipolar disorder diagnoses appeared to almost double, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Rochester Medical announces operating results for the fiscal year ended September 30, 2009
Rochester Medical Corporation today announced operating results for its fourth quarter and year ended September 30, 2009.
Baxter seeks European marketing authorization for HyQ to treat PI
Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.
› Verified 3 days ago